Empagliflozin improves pressure-overload-induced cardiac hypertrophy by inhibiting the canonical Wnt/β-catenin signaling pathway
Xun Yuan, Li Pan, Chi Zhang, Qiulian Zhu, Zexin Huang, Yuan Qin, Guiping Zhang, Zhimei Feng, Caixian Yang, Ning Hou · 2024
Read Empagliflozin improves pressure-overload-induced cardiac hypertrophy by inhibiting the canonical Wnt/β-catenin signaling pathway by Xun Yuan, Li Pan, Chi Zhang, Qiulian Zhu, Zexin Huang, Yuan Qin, Guiping Zhang, Zhimei Feng, Caixian Yang, Ning Hou (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11631586.txt.
Description
Xun Yuan and co-authors test a diabetes drug for heart thickening in mice in a 2024 study. Empagliflozin controls blood sugar, and trials hint it also shields the heart. How it protects heart muscle at the molecular level was still unclear.
Mice with a narrowed aorta, which forces the heart to thicken, got the drug daily or a plain vehicle. Treated mice showed less thickening, less scarring, and smaller heart cells. The drug dampened a growth pathway in heart tissue, and docking tests suggest it binds a receptor in that pathway. Mice bred with half that pathway's key protein also gained less damage when treated.
Catalog record
| CREATOR | Xun Yuan, Li Pan, Chi Zhang, Qiulian Zhu, Zexin Huang, Yuan Qin, Guiping Zhang, Zhimei Feng, Caixian Yang, Ning Hou |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |